PARVA Antibody

What is α-Parvin (PARVA) and why is it an important research target?

α-Parvin (PARVA) is a critical focal adhesion protein that couples integrins to the actin cytoskeleton. It plays essential roles in:

• Sarcomere organization and smooth muscle cell contraction

• Development of the embryonic cardiovascular system

• Sprouting angiogenesis and blood vessel development

• Reorganization of the actin cytoskeleton

• Establishment of cell polarity, adhesion, spreading, and directed cell migration

As part of the IPP (ILK-PINCH-PARVIN) complex, PARVA binds to F-actin, promoting F-actin bundling, which generates force for actin cytoskeleton reorganization required for dynamic cell adhesion events like cell spreading and migration .

How do I select the appropriate PARVA antibody for my specific application?

Selection should be based on:

Application compatibility: Different antibodies show varying efficacy across applications:

• For Western Blotting: Most antibodies work well, with optimal dilutions ranging from 1:200-1:1000

• For Immunohistochemistry: Select antibodies validated for IHC (p) with recommended dilutions of 1:50-1:500

• For Immunofluorescence: Choose antibodies with demonstrated reactivity in IF/ICC at 1:10-1:100 dilutions

• For Immunoprecipitation: Select antibodies specifically validated for IP (usually 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate)

Host species and clonality: Consider rabbit polyclonal for broader epitope recognition or mouse monoclonal (e.g., clone 3H9) for higher specificity .

Species cross-reactivity: Verify the antibody reacts with your species of interest - most PARVA antibodies react with human, mouse, and rat samples .

What are the key considerations for validating a PARVA antibody?

A comprehensive validation approach should include:

• Western blot verification: Confirm detection of the expected 43-55 kDa band in appropriate cell lines (U2OS, HeLa, HUVEC) or tissues (kidney, heart)

• Phospho-specific validation: For phospho-specific antibodies (e.g., phospho-S8), verify specificity using:

  • Phosphatase treatment controls

  • Phospho-mimetic mutants

  • Stimulation protocols that enhance phosphorylation

• Subcellular localization: Confirm expected focal adhesion localization pattern in IF/ICC experiments

• Knockout/knockdown controls: Use PARVA-depleted samples to confirm specificity and rule out cross-reactivity with β-parvin or γ-parvin

• Functional validation: Verify antibody effectiveness in disrupting protein-protein interactions in the IPP complex when used in functional studies

How can I optimize Western blot protocols for PARVA detection?

Optimal protocol for PARVA Western blotting:

• Sample preparation:

  • Lyse cells in RIPA buffer supplemented with phosphatase inhibitors

  • Include DTT (1 mM) and NaF (10 mM) to preserve phosphorylation states

  • Heat samples at 95°C for 5 minutes in reducing Laemmli buffer

• Gel electrophoresis and transfer:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Transfer to PVDF membrane at 100V for 1 hour or 30V overnight

  • Verify transfer efficiency with Ponceau S staining

• Antibody incubation:

  • Block with 5% BSA in TBST (for phospho-specific) or 5% milk (for total PARVA)

  • Incubate with primary antibody (1:1000 dilution) overnight at 4°C

  • Use HRP-conjugated secondary antibodies at 1:5000 for 1 hour at room temperature

• Detection considerations:

  • PARVA typically appears at 43-55 kDa depending on post-translational modifications

  • Enhanced chemiluminescence (ECL) is sufficient for detection in most samples

  • For phospho-specific detection, enhanced chemiluminescence plus (ECL+) may be required

What are the recommended protocols for immunofluorescence staining of PARVA in different cell types?

Optimized IF protocol for PARVA visualization:

• Cell preparation:

  • Culture cells on glass coverslips or chamber slides

  • For adherent cells, seed at 50-70% confluence 24h before fixation

  • For suspension cells, utilize cytospin centrifugation (5 × 10^4 cells per slide)

• Fixation and permeabilization:

  • Fix with 4% paraformaldehyde for 10-15 minutes at room temperature

  • Alternatively, use cold methanol (-20°C) for 10 minutes for better preservation of cytoskeletal structures

  • Permeabilize with 0.2% Triton X-100 in PBS for 5 minutes

• Blocking and antibody incubation:

  • Block with 5% normal serum from secondary antibody host species

  • Incubate with PARVA antibody at 1:50-1:100 dilution for 1-2 hours at room temperature

  • Wash thoroughly (3 × 5 minutes with PBS)

  • Incubate with fluorophore-conjugated secondary antibody (1:500) for 1 hour

• Co-staining recommendations:

  • Paxillin, ILK, or PINCH antibodies for focal adhesion visualization

  • Phalloidin for F-actin co-localization studies

  • DAPI for nuclear counterstaining

How can I perform successful immunoprecipitation of PARVA proteins in complex samples?

Optimized immunoprecipitation protocol:

• Lysate preparation:

  • Harvest cells in non-denaturing lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate)

  • Include protease and phosphatase inhibitors

  • Clear lysate by centrifugation (14,000 × g, 10 minutes, 4°C)

• Pre-clearing and immunoprecipitation:

  • Pre-clear lysate with Protein A/G beads (1 hour, 4°C)

  • Incubate cleared lysate with PARVA antibody (2-4 μg per mg protein) overnight at 4°C

  • Add Protein A/G beads and incubate for 1-3 hours at 4°C

  • Consider using antibody-conjugated beads for improved efficiency (e.g., α-Parvin (D7F9) XP® Rabbit mAb Sepharose Bead Conjugate)

• Washing and elution:

  • Wash beads 4-5 times with cold wash buffer

  • Elute bound proteins by boiling in 2× Laemmli buffer

  • For Co-IP applications, consider gentler elution methods using competing peptides

• Validation:

  • Run 5-10% of input alongside IP samples

  • Include IgG control to assess non-specific binding

  • Verify successful pull-down by Western blot

What are common issues when using PARVA antibodies and how can they be resolved?

Problem 1: Multiple bands in Western blot

• Cause: Detection of degradation products, splice variants, or post-translational modifications

• Solution:

  • Include fresh protease inhibitors in lysis buffer

  • Confirm specificity using PARVA-depleted samples

  • Test multiple antibodies targeting different epitopes

  • Use phosphatase treatment to eliminate phosphorylation-dependent bands

Problem 2: Weak signal in immunofluorescence

• Cause: Insufficient antibody concentration, improper fixation, or blocked epitopes

• Solution:

  • Try multiple fixation methods (PFA vs. methanol)

  • Increase antibody concentration or incubation time

  • Enhance antigen retrieval with citrate buffer or TE buffer pH 9.0

  • Use signal amplification methods (e.g., tyramide amplification)

Problem 3: High background in immunohistochemistry

• Cause: Non-specific binding, excessive antibody concentration, or inadequate blocking

• Solution:

  • Optimize blocking (increase to 5-10% serum)

  • Reduce antibody concentration

  • Include 0.1-0.3% Triton X-100 in antibody diluent

  • Pre-absorb antibody with non-specific proteins

Problem 4: Failed co-immunoprecipitation of PARVA with binding partners

• Cause: Harsh lysis conditions disrupting protein-protein interactions

• Solution:

  • Use milder detergents (0.5% NP-40 instead of 1%)

  • Include stabilizing agents (10% glycerol)

  • Cross-link proteins before lysis for transient interactions

  • Optimize salt concentration in buffers (150-300 mM)

How can I distinguish between different phosphorylation states of PARVA using antibodies?

Strategies for phospho-PARVA detection:

• Selective phospho-specific antibodies:

  • Use validated phospho-specific antibodies (e.g., anti-PARVA phospho-S8) to detect specific phosphorylation sites

  • Include non-phospho controls (phosphatase-treated samples) to confirm specificity

  • Consider using both phospho-specific and total PARVA antibodies in parallel

• Validation approaches:

  • Verify phospho-specificity using lambda phosphatase treatment

  • Use phosphomimetic (S→D/E) or phosphonull (S→A) mutants as controls

  • Employ kinase inhibitors to manipulate phosphorylation status

• Analytical methods:

  • Use Phos-tag SDS-PAGE to separate phosphorylated from non-phosphorylated forms

  • Perform 2D gel electrophoresis (isoelectric focusing followed by SDS-PAGE)

  • Consider mass spectrometry for comprehensive phosphorylation site analysis

• Functional significance analysis:

  • Compare phosphorylation status during cell cycle progression

  • Evaluate changes during cell adhesion/migration processes

  • Correlate with actin cytoskeleton reorganization events

How can I perform multiplexed detection of PARVA with other focal adhesion proteins?

Multiplexed detection strategies:

• Multi-color immunofluorescence:

  • Use primary antibodies from different host species (e.g., rabbit anti-PARVA with mouse anti-paxillin)

  • Apply species-specific secondary antibodies with distinct fluorophores

  • Include appropriate controls for bleed-through and cross-reactivity

  • Recommended combinations: PARVA (rabbit) + paxillin (mouse) + F-actin (phalloidin)

• Sequential immunostaining:

  • For antibodies from the same host species, use sequential staining with intermediate blocking

  • Apply the first primary antibody, detect with fluorophore-conjugated Fab fragments

  • Block with excess unconjugated Fab fragments

  • Apply the second primary antibody and detect with standard secondary antibody

• Proximity ligation assay (PLA):

  • Use for detection of protein-protein interactions (<40 nm proximity)

  • Apply primary antibodies against PARVA and its binding partners

  • Use species-specific PLA probes

  • Signal amplification generates fluorescent spots at sites of interaction

How can PARVA antibodies be used to study mechanical force transduction in focal adhesions?

Advanced methodologies for mechanobiology:

• Live-cell imaging approaches:

  • Express fluorescently-tagged PARVA constructs and perform FRAP (Fluorescence Recovery After Photobleaching)

  • Use PARVA antibodies to validate the localization and dynamics of tagged constructs

  • Apply PARVA antibodies in FRET-based tension sensors to map mechanical forces

• Substrate stiffness studies:

  • Analyze PARVA recruitment on substrates of varying rigidity (2-50 kPa)

  • Use PARVA antibodies to quantify focal adhesion maturation in response to ECM stiffness

  • Correlate PARVA localization with traction force microscopy data

• Force-dependent phosphorylation analysis:

  • Apply mechanical stretch or fluid shear stress to cells

  • Analyze PARVA phosphorylation status using phospho-specific antibodies

  • Correlate with changes in cell morphology and cytoskeletal organization

• Techniques for force manipulation:

  • Combine magnetic tweezers or optical tweezers with immunofluorescence

  • Apply local force to integrins and monitor PARVA recruitment/phosphorylation

  • Use PARVA antibodies for post-fixation analysis after force application

What are the considerations for using PARVA antibodies in studies of cardiovascular development and disease?

Cardiovascular research applications:

• Developmental studies:

  • Use PARVA antibodies to track expression during embryonic cardiovascular development

  • Apply to tissue sections with careful optimization of antigen retrieval methods

  • Combine with lineage markers to identify cell-specific expression patterns

• Disease model applications:

  • Monitor PARVA expression and localization in models of:

    • Cardiac hypertrophy and heart failure

    • Vascular remodeling and atherosclerosis

    • Angiogenesis and neovascularization

• Methodological considerations:

  • For heart tissue sections: Use paraffin-embedded sections with citrate buffer antigen retrieval

  • For cultured cardiomyocytes: Optimize fixation to preserve sarcomeric structures

  • For blood vessels: Consider en face preparations for endothelial cells

  • Include tissue-specific controls and cell-type markers

• Quantitative analysis approaches:

  • Measure PARVA intensity at intercalated discs vs. costameres in cardiomyocytes

  • Analyze PARVA/paxillin co-localization in response to hemodynamic forces

  • Quantify changes in PARVA phosphorylation during cardiac stress

How can I use PARVA antibodies in studying cancer cell migration and invasion?

Cancer research applications:

• Metastasis model systems:

  • Use PARVA antibodies to assess focal adhesion dynamics in 2D migration assays

  • Apply in 3D invasion models to visualize PARVA at invadopodia

  • Evaluate changes in phosphorylation status during epithelial-mesenchymal transition

• Correlation with clinical samples:

  • Optimize immunohistochemistry for PARVA detection in tissue microarrays

  • Evaluate expression patterns at tumor-stroma interfaces

  • Correlate with invasive fronts and metastatic potential

• Functional interference studies:

  • Use PARVA antibodies for neutralization in live cells (if cell-penetrating)

  • Validate knockdown/knockout efficiency at protein level

  • Compare phosphorylation states between primary and metastatic samples

• Advanced imaging approaches:

  • Super-resolution microscopy to visualize PARVA nanoscale organization

  • Correlative light-electron microscopy to relate PARVA localization to ultrastructure

  • Intravital imaging with validated antibodies in xenograft models

What are emerging applications of PARVA antibodies in understanding mechanotransduction signaling pathways?

Cutting-edge applications:

• Proteomics integration:

  • Use PARVA antibodies for immunoprecipitation followed by mass spectrometry

  • Identify force-dependent interactions within the adhesome

  • Map post-translational modification sites affected by mechanical stimuli

• Single-cell analysis:

  • Apply in imaging mass cytometry for multiplexed protein detection

  • Use for Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq)

  • Correlate protein expression with single-cell transcriptomics

• Liquid-liquid phase separation studies:

  • Investigate PARVA's role in biomolecular condensates at focal adhesions

  • Use antibodies to track redistribution during condensate formation

  • Apply in optogenetic systems to validate condensate components

• Therapeutic targeting validation:

  • Validate specificity of small molecule inhibitors targeting PARVA-dependent pathways

  • Use in combination with CRISPR screens to identify synthetic lethal interactions

  • Apply in patient-derived models to evaluate potential as biomarker or therapeutic target